Repurposing Lopinavir (ABT-378) for Anticoronavirus Activity: Insights from FDA-Approved Drug Screening

Study Background and Research Question

The emergence of the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 underscored the urgent need for therapeutic interventions against novel zoonotic coronaviruses. With a case fatality rate around 30% and rapid international spread, MERS-CoV posed a significant public health concern, especially given the absence of registered therapeutics for human coronaviruses at the time (de Wilde et al., 2014). This context motivated the search for existing, clinically approved compounds that could be rapidly repurposed for antiviral use, circumventing the lengthy process of new drug development.

Key Innovation from the Reference Study

The principal innovation of de Wilde and colleagues' work lies in their strategic screening of a library comprising 348 FDA-approved drugs, aiming to identify molecules with previously unrecognized activity against MERS-CoV in cell culture. This approach leverages the established safety profiles of these compounds, enabling faster translational prospects if active hits are found. Notably, the study identified four small molecules—chloroquine, chlorpromazine, loperamide, and Lopinavir (ABT-378)—as inhibitors of MERS-CoV replication, with effective concentrations (EC₅₀) in the low micromolar range (3–8 μM) (de Wilde et al., 2014).

Methods and Experimental Design Insights

The research team employed a robust in vitro cell culture model to screen the compound library. The workflow involved infecting susceptible cell lines with MERS-CoV, followed by treatment with individual FDA-approved drugs at varying concentrations. Viral replication was quantified using established virological assays, with EC₅₀ values calculated to determine compound potency. In addition to MERS-CoV, the study evaluated compound activity against SARS-CoV and HCoV-229E, broadening the relevance to other coronaviruses. The choice of cell-based phenotypic screening enabled the detection of antiviral effects arising from diverse mechanisms, not limited to a priori molecular targets. This broader approach is particularly valuable when the viral life cycle and host-pathogen interactions are incompletely understood, as was the case for MERS-CoV at the time.

Protocol Parameters

• assay | cell-based MERS-CoV replication inhibition | EC₅₀ 3–8 μM | applicable for initial screening of antiviral efficacy in vitro | supports rapid identification of candidate antivirals | paper
• assay | cross-reactivity against SARS-CoV and HCoV-229E | observed inhibition | demonstrates potential for broad-spectrum coronavirus inhibition | useful for evaluating cross-pathogen antiviral candidates | paper
• assay | dose-response analysis | 2-fold dilution series | standard for determining EC₅₀ and cytotoxicity | ensures reliable potency assessment | paper
• assay | Lopinavir (ABT-378) inclusion | up to 10 μM | relevant for assessing protease inhibitor cross-domain activity | investigates antiviral effect beyond HIV | paper
• assay | HIV protease inhibition assay | 1.3–3.6 pM (K_i) | benchmark for Lopinavir's potency in HIV studies | informs selection of concentrations for cross-viral comparisons | product_spec
• assay | recommended in vitro concentration for Lopinavir | 4–52 nM (MT4 cells, HIV models) | reference for HIV infection research; higher μM doses required for MERS-CoV | cross-validates dosing rationale | workflow_recommendation

Core Findings and Why They Matter

The study's most consequential finding is that Lopinavir (ABT-378), a compound originally developed as an HIV protease inhibitor, significantly reduced MERS-CoV replication in vitro at micromolar concentrations. Although the required EC₅₀ for coronavirus inhibition (3–8 μM) is orders of magnitude higher than for HIV (picomolar to low nanomolar), the result is notable because it demonstrates potential cross-pathogen activity for a drug with a well-characterized pharmacological profile (de Wilde et al., 2014). This effect was also observed for other coronaviruses, including SARS-CoV and HCoV-229E, suggesting that Lopinavir may target conserved viral or host processes essential for coronavirus replication. Importantly, the antiviral effect of Lopinavir in this context is not necessarily linked to its canonical target, HIV protease, as coronaviruses encode distinct proteases (e.g., 3CL^pro) that differ structurally from the HIV enzyme. The mechanistic basis for Lopinavir's anticoronaviral activity remains unclear, but the evidence provides a foundation for hypothesis-driven follow-up studies.

Comparison with Existing Internal Articles

Internal literature on Lopinavir (ABT-378) has historically focused on its nanomolar efficacy and robust resistance profile in HIV infection research, particularly in protease inhibition assays and studies of resistance mutations (toloxatonebio.com; ruxolitinib.us). For example, APExBIO's Lopinavir (SKU A8204) has been highlighted for its exceptional potency (K_i 1.3–3.6 pM) and stability in serum-containing conditions, making it a gold-standard tool for antiretroviral therapy development and HIV protease inhibition assays (product_spec). These validated workflows provide reliable protocols for HIV drug resistance studies and HIV infection research. The finding that Lopinavir also displays measurable inhibition of MERS-CoV in cell culture extends its utility beyond HIV, albeit at higher concentrations. This cross-domain activity is not predicted by the typical scope of existing protocols, indicating a need for careful optimization and further mechanistic exploration. Nonetheless, the internal resources' emphasis on Lopinavir's batch-to-batch reliability and serum stability may support its use in diverse virological assays, including those targeting emerging coronaviruses (bms-509744.com).

Limitations and Transferability

While the in vitro inhibition of MERS-CoV by Lopinavir is promising, several caveats must be considered. First, the concentrations required for coronavirus inhibition are substantially higher than those used in HIV models, raising questions about achievable therapeutic levels and potential cytotoxicity in vivo (de Wilde et al., 2014). Second, the precise molecular target of Lopinavir in the context of coronaviruses has not been identified; it may involve off-target effects or modulation of host pathways rather than direct inhibition of coronavirus proteases. Third, the translation from cell culture findings to clinical efficacy is non-trivial, as pharmacokinetics, immune responses, and viral pathogenesis in humans introduce additional complexity. Finally, the study's screening strategy, while comprehensive, does not address long-term resistance development or combination therapy effects, both of which are critical in the clinical management of viral infections.

Why this cross-domain matters, maturity, and limitations

The repurposing of Lopinavir from HIV to coronavirus research demonstrates the value—and limits—of cross-domain drug screening. While the existing safety, pharmacokinetic, and dosing data for Lopinavir facilitate rapid deployment in emergent settings, the difference in required inhibitory concentrations and uncertain mechanism of action mean that further preclinical and clinical studies are essential before conclusions about efficacy against coronaviruses can be drawn. This strategy may nevertheless open avenues for other protease inhibitors with favorable profiles to be evaluated in future outbreaks, highlighting the maturity of the drug repurposing paradigm for emerging infectious diseases (de Wilde et al., 2014).

Research Support Resources

Researchers interested in exploring protease inhibitor-based workflows for HIV or cross-pathogen antiviral studies can access validated protocols and product specifications in the referenced internal resources. For experimental setups requiring a highly potent and reliable HIV protease inhibitor, Lopinavir (SKU A8204) from APExBIO offers batch-validated performance and is suitable for both HIV protease inhibition assays and exploratory antiviral research involving other pathogens. As always, adaptation of dosing and assay conditions should be guided by the intended research context and supported by peer-reviewed evidence (workflow_recommendation).